All News

What increases risk of RA-assoc #bronchiectasis, separate from #RA-ILD? Results from @BrighamResearch find seropositivity (esp high +ve RF/CCP), older age, disease duration, & low BMI incr. risk of isolated bronchiectasis in RA. #ACR21 Abs#0288 @RheumNow https://t.co/jvvRucqTjL https://t.co/aFCfxrbUdV

Demographic, Lifestyle, and Clinical Risk Factors for Rheumatoid Arthritis-Asso…

Dr. Petri et al showed transition between lupus anticoagulant (-) to (+), (+) to (-), and (+) or (-) to thrombosis could be estimated by multistate Markov model. #ACR21 Abst#0076 @RheumNow https://t.co/oIvbak4lV4

Retrospective study of FAERS database: 186 irAE w/rheum manifestation 👉4.7% of all AEs 👉Arthritis, myositis, Sjogren, sarcoidosis were frequent 👉myositis assc w/ durvalumab, avelumab, atezolimumab and cemiplimab #ACR21 Abstr#0438 #Plenary @rheumnow https://t.co/t8UQWQicFc https://t.co/FGo6WCDQTp

Rheumatological Immune-Related Adverse Events of Immune Checkpoint Inhibitors B…

@BethIWallace et al. on fibromyalgianess and GC in #rheumatoidarthritis pts. Accdg to their study, pts w/⬆ levels of fibromyalgianess at BL had higher odds of GC persistence on ffup. Something to consider when evaluating need for GC adjustment. @RheumNow #ACR21 abs0120 https://t.co/MTWEXGHJ2n

Retrospective study of cancer pts Rx w/ ICI and autoimmune Ab (ANA, RF, CCP, SSA/SSB, ANCA) 👉152 pts 👉59% had irAE 👉preICI Ab+⬆️odds of irAE (OR 17.5 95% CI 1.76-174, p=0.015) 👉strong assc b/t +RF and +CCP for ICD-arthritis #ACR21 Abst#0440 @Rheumnow https://t.co/kUv5ddSAnY

Association Between Rheumatic Autoantibody Positivity and Immune-related Advers…

Large case-control study (n=8028) to identify baseline predictors of rheum irAEs after immune checkpoint inhibitor initiation for cancer. Type of cancer (melanoma, GU), combination ICI, pre-existing autoimmune disease, and recent GC use each had higher odds of rheum irAE #ACR21 https://t.co/rHI6VQ37QB

#ClinicalPearl Joint clinic btwn ophthalmology & #rheumatology helps make dx & Rx work. #ACRBest #ACR21 see work up of inflammatory eyes disease. All are allowed one acute ant uveitis- ? dogma maybe work up all. 6S117 https://t.co/Wwdv3N66HS

#ACR21 Abst#0290: Ever wonder about other predictors of mortality in pts w/ RA-Lung Disease besides ILD (OR 2.3) or older age? ⭐︎ ↑ mortality associated w/ pleural effusions (OR 3.3) AND, notably... ⭐︎MTX use was protective (OR 0.4)!!! @RheumNow https://t.co/KKRkQVY2pf https://t.co/JsU2Rqzi6R

Developing a Score to Predict Preclinical Interstitial Lung Disease in Patients…

This study looked into the prevalence of subclinical atherosclerosis in #rheumatoidarthritis pts w/n 5 yrs of dx using carotid US. 📌vs. controls, RA pts had ⬆ CPs, cIMT ❗Screen RA pts for CV risk early on in their diagnosis @RheumNow #ACR21 abs0271 https://t.co/btU6IcM3xb

ASAS-PerSpA worldwide study: axSpA most common SpA from in family hx. Except in Middle Eastern/N. African pts, a FH of axSpA associated w/ +HLA-B27 in axSpA pts. PsO and IBD FH more likely -HLA-B27 . FH of ReA rare. Abs 0368 #ACR21 #RheumNow @RheumNow https://t.co/iHBccAcvLi https://t.co/FCoyVg3MGw

Geographical Prevalence of Family History in Patients with Axial SpA and Its As…

#ACR21 Abst#0293 RA patients with lung disease have increased rates of SSc-specific autoantibodies compared to RA w/o lung disease. ▶️ Suggests we may need to investigate further into overlap phenotype in RA-ILD @Rheumnow https://t.co/04FFuBUKmA https://t.co/A83kaie2gr

https://bit.ly/3mPlqkW

#ClinicalPearl. ‘my eye hurts-what’s going on!’ Dr Palestine says Ophthalmologists don’t agree on uveitis naming/ethology & worse - Rheums & eye specialists don’t speak language. Need to know infections are r/o (syphillis, CXR) & if active uveitis to ⬆️Rx #ACR21 @RheumNow https://t.co/7LkhJnUKXK

We should aim for early treatment and good retention in ax-SpA to prevent structural evolution. >12 months of TNFi treatment in the previous 2 years associated w/ ⬇️ radiographic progression of SIJ in r- and nr-axSpA in GESPIC, #Abst0174 @RheumNow #ACR21 https://t.co/2V1q4dUwFO https://t.co/lxQU4zAP1I

Tumor Necrosis Factor Inhibitors Show a Delayed Effect on Radiographic Sacroili…

Retrospective French study found adding JAKi may be helpful in refractory AOSD. No complete response noted and no beneficial effect as monotherapy. Possible difference between JAKi? Abs 0195 #ACR21 #RheumNow #ACRbest @RheumNow https://t.co/J8kLJpJ39o https://t.co/aVsfCQ8CyV

JAK Inhibitors in Refractory Adult and Childhood-Onset Still's Disease - A…

Our latest article on outcomes of patients with vasculitis and PMR and COVID-19 published in @TheLancetRheum . @rheum_covid project with co-leads @SattuiSEMD and @EBRheum . https://t.co/8NTAafdYRA

https://www.sciencedirect.com/science/article/pii/S2665991321003167

#Fatigue is common in pts w/ #PsA- what is the impact on short-term disability? Study of ~1200 pts finds greater annual short-term disability in pts with PsA & fatigue than w/o fatigue. Impact on QoL, work & socioeconomic costs. @RheumNow #ACR21 Abs#0239 https://t.co/9yNBOovm2L https://t.co/l4tn0TSld1

Work Disability Associated with Fatigue in Patients with Psoriatic Arthritis – …

📌Pre-Test Probability in GCA ESR/CRP can be normal: ~10% of pts at diagnosis -20-40% at time or relapse #ACR21 #ACRAmbassador #RheumTwitter https://t.co/kenaD31pYa

Machine learning predicted lupus nephritis in #SLE patients in real world data #ACR21 @RheumNow #abst0324 https://t.co/67HBT7F2GO

Dr Doliner @zach_wallace_md on ILD in AAV. ILD in 13% - of which 76% fibrotic. UIP most common. Most MPO+, but also rarely seen with PR3+. 47% ⬆️ risk of death. Abstr#0430 #ACR21 @RheumNow https://t.co/6MnxqW92bz

Dr Preger report 9 novel aminoacyl tRNA synthetases in IIM patients. May these allow us to spare more patients biopsy? Abstr#0001 #ACR21 @RheumNow https://t.co/ikNXCEOeuj

Topics

All News

Do you get our email newsletter?